Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and Ascites

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 7, 2012, Pages 815-818

  Kalambokis, Georgios N ^a   Mouzaki, Athanasia ^b   Rodi, Maria ^b   Pappas, Konstantinos ^a   Fotopoulos, Andreas ^a   Xourgia, Xanthi ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Clinical trial; Cytokine; Hyperdynamic circulation; Kidney disease

Indexed keywords

ALDOSTERONE; CREATININE; DIURETIC AGENT; ENDOTOXIN; FUROSEMIDE; INTERLEUKIN 6; PENTETATE TECHNETIUM TC 99M; RENIN; RIFAXIMIN; SODIUM; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALCOHOL LIVER CIRRHOSIS; ALDOSTERONE BLOOD LEVEL; ARTICLE; ASCITES; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DOPPLER ECHOGRAPHY; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMODYNAMICS; HUMAN; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NATRIURESIS; PLASMA CLEARANCE; PLASMA RENIN ACTIVITY; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; TREATMENT DURATION; UREA BLOOD LEVEL;

ANTI-BACTERIAL AGENTS; ASCITES; BLOOD PRESSURE; CARDIAC OUTPUT; ENDOTOXINS; HEMODYNAMICS; HUMANS; INTERLEUKIN-6; KIDNEY; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RENIN; RIFAMYCINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862664992     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.02.025     Document Type: Article

References (19)

1. Blendis L., Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001, 89:221-231.
2. Garcia-Tsao G., Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18:353-372.
3. Lin R.S., Lee F.Y., Lee S.D., et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995, 22:165-172.
4. Albillos A., de la Hera A., González M., et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003, 37:208-217.
5. Lee F.Y., Lu R.H., Tsai Y.T., et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol 1996, 31:500-505.
6. Genescà J., Martí R., Rojo F., et al. Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut 2003, 52:1054-1059.
7. Navasa M., Follo A., Filella X., et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998, 27:1227-1232.
8. Clemente C., Bosch J., Rodés J., et al. Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis. Gut 1977, 18:556-560.
9. Koo H.L., DuPont H.L. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010, 26:17-25.
10. Vlachogiannakos J., Saveriadis A.S., Viazis N., et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009, 29:992-999.
11. Wiest R., Das S., Cadelina G., et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999, 104:1223-1233.
12. Rasaratnam B., Kaye D., Jennings G., et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003, 139:186-193.
13. Chin-Dusting J.P., Rasaratnam B., Jennings G.L., et al. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997, 127:985-988.
14. Lopez-Talavera J.C., Cadelina G., Olchowski J., et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996, 23:1616-1621.
15. Nakatani Y., Fukui H., Kitano H., et al. Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver 2001, 21:64-70.
16. Levy M., Wexler M.J. Subacute endotoxemia in dogs with experimental cirrhosis and ascites: effects on kidney function. Can J Physiol Pharmacol 1984, 62:673-677.
17. Shahid M., Francis J., Majid D.S. Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol 2008, 295:F1836-F1844.
18. Tarao K., Moroi T., Hirabayashi Y., et al. Effect of paromomycin sulfate on endotoxemia in patients with cirrhosis. J Clin Gastroenterol 1982, 4:263-267.
19. Runyon B.A., Borzio M., Young S., et al. Effective of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis. Hepatology 1995, 21:1719-1724.